Cambridge Epigenetix Ltd (CEGX), a spinout of the University of Cambridge that makes epigenetics tools, has raised $5.5 million from venture capital organisations in a Series A round. The financing was led by New Science Ventures LLP of New York, New York.
Christopher Viehbacher has been removed as chief executive officer of Sanofi SA by a unanimous vote of the board of directors, the company announced early Wednesday.
Bristol-Myers Squibb Company has purchased an exclusive option to acquire F-star Alpha Ltd, a Cambridge, UK-based company which has a preclinical drug candidate targeting HER2-positive tumours including those that are refractory to trastuzumab and pertuzumab.
Novartis reported an improvement in profit margins for the third quarter with the result that operating profit increased by 14% from a year earlier to $2,980 million. In constant currencies the operating result was ahead by 18%.
ImevaX GmbH, a 2014 spin-out of the Technische Universität Mϋnchen (TUM) in Germany, has completed a €7.5 million Series A financing round to advance a candidate vaccine against Helicobacter pylori, a major cause of stomach ulcers.
Advent Life Sciences, which is part of Advent Venture Partners LLP, has raised £145.5 million for a second fund to seed and build life science companies in the UK, continental Europe and the US. The partnership said the amount raised exceeded its target.
Olaparib, a drug with an unusual clinical history, has been given a positive scientific review by the European Medicines Agency paving the way for its use as a treatment for women with a subtype of ovarian cancer.
Novartis International AG has reached agreement to sell its influenza vaccines business to CSL Ltd of Australia for US $275 million, subject to regulatory approvals. The transaction is expected to close in the second half of 2015.
Shire Plc has raised its guidance for 2014 following a strong third-quarter and nine-month financial performance. The results don’t include a $1.6 billion break fee due it from AbbVie Inc which walked away from a proposed takeover earlier this month.
Erytech Pharma SA, which publically offered its shares for the first time in April 2013, has returned to the Paris Euronext exchange for €30 million in an offering that was 68% subscribed by US institutions.